Geburtshilfe und Frauenheilkunde

LinksSchließen

Referenz

Sikov WM, Berry DA, Perou CM et al.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015;
33: 13-21

Bibliographische Angaben herunterladen

Aufrufen in: